We welcome inquiries from the media, and encourage reporters, editors, bloggers and other journalists to contact us for information about our company and research programs at media@sarepta.com or 617.274.4052. For other inquiries, please visit our Contact Page.



Sarepta Therapeutics is based in Cambridge, Massachusetts.

Our stock is listed on NASDAQ under the symbol “SRPT.”

Sarepta's business is focused on the discovery, development and commercialization of RNA-targeted therapies for rare and infectious diseases.




Archived Press Releases

02/21/17 Sarepta Therapeutics Agrees to Sale of Priority Review Voucher for $125M
02/15/17 Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2016 Financial Results and Recent Corporate Developments on February 28, 2017
01/31/17Download PDFSarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/10/17Download PDFSarepta Therapeutics Enters into License Agreement with Nationwide Children’s Hospital for Galgt2 Gene Therapy Program
01/10/17Download PDFSarepta Therapeutics Enters into Research Agreement and Option Agreement with Nationwide Children’s Hospital for Microdystrophin Gene Therapy Program
01/03/17Download PDFSarepta Therapeutics to Present Company Overview at the 2017 35th Annual J.P. Morgan Healthcare Conference

This section of our website may contain dated or archived information which should not be considered current and may no longer be accurate. For current information, you are encouraged to review our most recent official corporate documents on file with the U.S. Securities and Exchange Commission.